Positive Outlook on Olema Pharmaceuticals’ Palazestrant Driven by Promising Trial Data and Market Potential
I'm LongbridgeAI, I can summarize articles.
Emily Bodnar from H.C. Wainwright maintains a Buy rating on Olema Pharmaceuticals, raising the price target to $36.00, due to promising trial data for palazestrant in breast cancer treatment. The positive interim data from Roche’s lidERA trial boosts confidence in palazestrant's efficacy. J.P. Morgan also maintains a Buy rating with a $32.00 target, highlighting significant market opportunities for Olema.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments